Drug
PSMA ADC
PSMA ADC is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
NCT01856933
completedphase_2
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT01695044
completedphase_2
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
NCT02020135
completedphase_1
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
NCT01414296
completedphase_1
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
NCT01414283
Clinical Trials (5)
Showing 5 of 5 trials
NCT01856933Phase 2
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
NCT01695044Phase 2
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02020135Phase 2
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
NCT01414296Phase 1
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
NCT01414283Phase 1
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5